Dr. Mitchell D. Lee, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Brody School of Medicine at East Carolina University (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 49
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Brody School of Medicine at East Carolina University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NC license 35692 -
Critical Care Medicine (Internal Medicine) Physician
NC license 35692 -
Sleep Medicine (Internal Medicine) Physician
NC license 35692
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health New Hanover Regional Medical Center Wilmington, NC
Medical groups
- Wilmington Health PLLC (369 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 49
- Services billed
- 61
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 322 | 239 |
| Critical care, first 30-74 minutes | 208 | 99 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 128 | 59 |
| Test to examine how well the lungs exchange gases | 125 | 117 |
| Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 115 | 115 |
| Test to determine lung volumes using sensors | 105 | 99 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 87 | 84 |
| Established patient office or other outpatient visit, 40-54 minutes | 85 | 68 |
| Established patient office or other outpatient visit, 20-29 minutes | 83 | 79 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 42 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Wilmington, NC | 42 |
| Montelukast Sodium Other prescribers in Wilmington, NC | 41 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Wilmington, NC | 40 |
| Stiolto Respimat (tiotropium br/olodaterol hcl) Other prescribers in Wilmington, NC | 25 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Wilmington, NC | 19 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Wilmington, NC | 18 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Wilmington, NC | 15 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Wilmington, NC | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $298 in total to this clinician.
| GlaxoSmithKline, LLC. | $284 |
|---|---|
| Resmed Corp | $13.85 |
| Food and Beverage | $298 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,650 in research payments for these studies, mostly to the institutions running them.
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.